Demodex blepharitis agents (lotilaner/Xdemvy) - Prior Authorization Criteria
Customize your policy alerts
Sign up for allcareadvantage Policy 123.1 alerts
Get alerted when Policy 123.1 changes without checking for updates manually.
Monitor payer policy activity
Defines prior authorization and coverage criteria for lotilaner ophthalmic solution (Xdemvy) for treatment of Demodex blepharitis for AllCare Advantage members.
No material clinical or coverage changes in this revision.
Coverage Criteria
Initial therapy
Covered when ALL of the following are met
If all elements are met, approve up to 6 weeks with a quantity limit of 10 mL for a single fill.
Renewal therapy
Renewal covered when ALL of the following are met
If renewal criteria are not met, do not approve continuation of therapy.
There are no explicit exclusions listed in this policy beyond failure to meet the required coverage criteria. Coverage for lotilaner ophthalmic solution (Xdemvy) is granted only when all elements of the applicable criteria are met; failure to satisfy any required criterion will result in denial (see denial triggers and required documentation).
Use is not authorized when the submission lacks required documentation or evidence of prior therapies. Specifically, requests will be denied if there is no sufficient documentation to support a diagnosis of Demodex blepharitis, if there is no documentation of an adequate trial (or documented contraindication) of lid hygiene, if objective confirmation of Demodex infestation (e.g., microscopic examination) is absent, or if there is no documentation of a trial of (or contraindication to) oral ivermectin.
Coding & Supply Limits
| Xdemvy (lotilaner) ophthalmic solution | Formulary agent; lotilaner ophthalmic solution (no numeric billing codes provided in document) |
Provider Actions & Requirements
Prior authorization required; limits on initial approval
Prior authorization is required for Xdemvy (lotilaner) ophthalmic solution. When all coverage criteria are met, initial approval is up to 6 weeks with a quantity limit of 10 mL for a single fill.
Step therapy: lid hygiene then oral ivermectin
Before approving lotilaner, the provider must document a trial of lid hygiene (or a documented contraindication) and a trial of oral ivermectin (or a documented contraindication).
- Documented adequate trial of (or contraindication to) lid hygiene
- Documented trial of (or contraindication to) oral ivermectin
Documentation required to support authorization
The provider must submit documentation supporting the diagnosis and objective confirmation of Demodex blepharitis and records of prior therapies to meet authorization criteria.
- Sufficient documentation to support a diagnosis of Demodex blepharitis
- Objective documentation (e.g., microscopic examination) confirming Demodex
- Documentation of trial of (or contraindication to) lid hygiene
- Documentation of trial of (or contraindication to) oral ivermectin
- For renewals: documentation supporting continued need, including objective documentation of recurrent infestation with significant symptoms
Triggers for denial
Requests will be denied if required documentation, objective confirmation, or required prior therapy trials/conditions are not provided or if the patient does not meet the FDA-approved indication.
- Insufficient documentation to support a diagnosis of Demodex blepharitis
- Patient does not meet FDA-approved indication for age/dosing
- No documented trial (or contraindication) of lid hygiene
- No objective documentation (e.g., microscopic exam) of Demodex
- No documented trial (or contraindication) of oral ivermectin
Background
Blepharitis is a chronic eyelid inflammation that often requires long-term care. The mainstay of management is lid hygiene, including cleansing, exfoliation, and use of warm compresses. Demodex mites (Demodex folliculorum) are implicated in a subset of chronic anterior blepharitis cases; lotilaner ophthalmic solution (Xdemvy) is an FDA-approved therapy that targets these mites.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.